Dose-escalation Study to Assess the Safety and Tolerability of Sub-cutaneous Injections of a Peptide-loaded Plasmacytoid Dendritic Cell Line (GeniusVac-Mel4) in Patients With Melanoma
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs GeniusVac Mel4 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; First in man
- 10 Nov 2017 Status changed from recruiting to completed.
- 28 Jun 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
- 28 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.